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INTRODUCTION
Eccrine porocarcinoma (EP), a particular malignant 
sweat gland tumor, represents only 0.005% of epithelial 
cutaneous neoplasms. The first reported case was attributed 
to Pinkus and Mehregan,1 and since then, only a few 
subsequent studies have been presented. Among these 
reported series, the majority describe aggressive tumor 
behavior.2-5
In this study, we present the features and outcomes of 
eight fully documented cases (one of the 10 largest single-
center studies ever published). Although we have previously 
published a detailed case showing bone invasion and 
lymph node metastasis,6 the current study focuses on the 
complexities of diagnosis and the overall clinical features 
that render this ailment difficult to accurately diagnose.
PATIENTS AND METHODS
Between 1990 and 2005, three surgeons at a single center 
evaluated and treated eight patients with confirmed EP. 
The study was approved by the Institutional Ethics Board 
Committee (number 1519/07). Relevant clinical data were 
assessed. The TNM classification system for cutaneous 
carcinomas was applied in each case. A surgical pathologist 
with expertise in cutaneous malignancies reviewed all of the 
hematoxylin and eosin (H&E)-stained slides.
The diagnosis was established based on the presence 
of malignant cell clusters that showed an invasive 
architectural pattern, ductal and eccrine differentiation 
and cytological pleomorphisms (Figure 1). The ductal 
differentiation varied from small intracytoplasmic lumens 
to mature well-established ducts that were lined with a 
thin eosinophilic layer. No tumor displayed granular cells 
or decapitated lumens, thus ruling out the possibility of 
apocrine differentiation. The criteria used to define invasion 
included tumor desmoplasia and/or the presence of irregular 
dermis-infiltrating cell clusters. Other observed features 
included basaloid and clear-cell patterns as well as squamous 
differentiation.
The parameters evaluated concerning prognostic analysis 
were the following: lymphovascular invasion, perineural 
invasion, necrosis and the mitotic index. The mitotic index 
was analyzed qualitatively, and the cutoff for high or low 
index was 14 mitotic cells per high-power field (HPF). 
Vertical growth was assessed from the granular layer 
to the deepest site of invasion, as noted in the Breslow 
classification. Any tumor presenting vertical growth greater 
than 7 mm was considered thick.
RESULTS
The mean age was 67 years old. A single primary lesion 
was present in each case. All patients were Caucasian. Three 
cases displayed previous contact with agrotoxic agents, 
while two others admitted to lifelong sunlight exposure 
without adequate protection. After the initial biopsies 
(performed in primary care clinics and analyzed by non-
expert diagnostic histopathologists), half of the patients 
had an inaccurate or incomplete diagnosis, as presented 
in table 1. The mean time until definitive treatment by a 
cancer center was 36 months, ranging from 7 months to 120 
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months. The mean size of the primary lesion was 48 mm, 
ranging from 10 mm to 100 mm. Five patients (62.5%) had 
infected lesions at the initial examination. The clinical and 
pathological characteristics upon admission are shown in 
table 2.
None of the tumors were classified as pure “in situ” 
neoplasia. Only a single case contained all the morphological 
criteria within the incisional biopsy. Three cases reported 
an initial suspicion of EP; however, the absence of ductal 
differentiation prevented a definitive diagnostic conclusion 
at that time.
Four cases had inaccurate diagnosis at first biopsy. A 
basaloid cell pattern was present in the specimen analysis 
of one case, and the absence of ductal differentiation led 
to the incorrect diagnosis of basal cell carcinoma. Another 
tumor showed extensive clear-cell components, leading 
the pathologist to overlook the ductal differentiation and 
report the final diagnosis as squamous cell carcinoma of the 
clear-cell subtype. Those two cases were clearly defined as 
EP after surgical resection because sufficient material for 
the proper analysis of ductal differentiation was obtained. 
A third case yielded only a small amount of tissue, and the 
Figure 1 - Eccrine Porocarcinoma – Histology. A. diffuse infiltrative pattern, B. atypical elongated cells and central groove, C. duct formation, D. mitotic 
figure (arrow)
Table 1 - Pathological report from the initial biopsy for eight cases with an eventual definitive eccrine porocarcinoma diagnosis.
Patient Primary Lesion Size (mm) Diagnosis after Initial Biopsy
#1 65 Excisional biopsy as initial treatment
#2 50 Ulcerated basal cell carcinoma
#3 35 Ulcerated epithelial neoplasm suggestive of porocarcinoma
#4 50 Round cell undifferentiated neoplasm
#5 20 Clear cytoplasm cell carcinoma (suggestive of porocarcinoma)
#6 10 Adnexal skin carcinoma (suggestive of porocarcinoma)
#7 100 Malignant eccrine poroma
#8 60 Squamous cell carcinoma – invasive clear-cell variant
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analysis was thus impaired. As a consequence, an incorrect 
diagnosis of “undifferentiated” small round-cell neoplasm 
was reported. Definitive surgery gave better-quality tissue 
for an accurate analysis, and the final diagnosis was EP. The 
fourth case had inconclusive initial analysis and we thus 
performed a complete excisional biopsy which rendered the 
diagnosis of EP. The histopathological prognostic factors are 
shown in table 2.
The standard treatment performed was wide resection. 
There is no clear recommendation in the literature regarding 
surgical margins for EP tumors. As such, we used our 
routine protocol for non-melanoma skin cancer, applying 
clear margins of at least 10 mm. In three patients, the 
resection was followed by a lymphadenectomy (inguinal or 
cervical). A single patient received palliative chemotherapy 
after unresectable local recurrence, while another two 
patients underwent adjuvant radiation therapy, one for close 
resection margins and the other because of lymph node 
macrometastasis.
The mean follow-up time was 74 months. Of the eight 
cases, six patients remain alive: Five patients have no 
evidence of disease, and one patient has confirmed regional 
recurrence. The two other patients died of EP-related 
complications. One of these two patients had an extensive 
recurrence, and his age did not allow further treatment. The 
second patient died following a second recurrence, three 
years after the initial diagnosis.
DISCUSSION
We have presented the approach and outcomes of eight 
EP cases. The study stresses the major problems with this 
particular type of tumor and the delay in definitive treatment 
attributed to the tumor’s indolent behavior or misleading 
clinical diagnosis upon inexpert medical evaluation. 
Pathologically speaking, this neoplasia demonstrated an 
aggressive behavior compared with common nonmelanoma 
skin cancer.
EP has a propensity to arise on the lower limbs (44%), 
trunk (24%) or head and neck region (24%).3-4,7-8 However, 
rare cases of penile involvement have been reported.8 
Morphologically, tumors vary greatly in size, from less than 
1 cm up to 10 cm. A long period of clinical history is often 
encountered (up to 50 years) because some of these tumors 
could have arisen from a preexisting benign eccrine poroma. 
Regional lymph node metastases are found in about 20% 
of patients, and distant metastases arise in about 10% of 
patients.4-5,8
The disease may appear nodular, infiltrative, ulcerated or 
polypoid. Multinodularity, ulceration and rapid growth may 
be associated with either local recurrence or metastasis.2 
The clinical differential diagnoses of these lesions include 
seborrheic keratosis, pyogenic granuloma, amelanotic 
melanoma, squamous cell carcinoma, basal cell carcinoma, 
verruca vulgaris, and metastatic adenocarcinoma.2,3
As we have shown, the initial pathology report can easily 
lead to a misdiagnosis. Even defined EPs may show some 
kind of basal or squamous differentiation.9 The tumor is 
typically formed of cohesive basaloid epithelial cells. This 
morphological appearance can include squamous cells, clear 
cells, spindle cell differentiation, mucous cell metaplasia, a 
Paget phenomenon and colonization by melanocytes.6-7,10 
Clear-cell changes are frequently observed and are attributed 
to moderate amounts of glycogen, as detected by periodic 
acid-Schiff (PAS) and PAS after digestion with diastase.5,8 
Immunohistochemical techniques are not strictly necessary; 
Table 2 - Clinical patterns from eight patients with a definitive eccrine porocarcinoma diagnosis.
Case Age Sex Site Tumor 
Thickness 
(mm)
Mitotic 
Index 
(per HPF)
Necrosis LVI PNI LN Stage* Status OS
#1 61 F Scalp < 7 > 14 Yes Yes Yes Yes III DOD 36
#2 64 F Shoulder > 7 < 14 Yes Yes No No II NED 180
#3 50 F Leg > 7 < 14 Yes Yes Yes Yes III NED 360
#4 64 F Leg > 7 < 14 Yes No Yes No II NED 230
#5 73 M Tight < 7 < 14 No No No No I NED 18
#6 55 M Forearm < 7 < 14 No No No No I NED 36
#7 82 F Buttock > 7 > 14 Yes Yes Yes Yes III DOD 6
#8 58 M Neck > 7 > 14 Yes Yes No Yes III AWD 18
LVI: lymphovascular invasion, PNI: perineural invasion, OS: overall survival (in months), LN: lymph node metastasis, *TNM (section: 
cutaneous carcinoma), NED: no evidence of disease, DOD: died of disease, DOI: died of intercurrent disease, AWD: alive with recurrent 
disease.
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however, they may be used to confirm the diagnosis. The 
cells that line the neoplastic ducts and clefts are positive 
for carcinoembrionic antigen and negative for S100 protein 
(myoepithelial cells from the glandular portion are positive 
for S100 protein).3-4 These findings confirm a primitive 
eccrine ductal differentiation.
Clinicians will often render a worse prognosis because 
of a mitotic index of more than 14 mitotic cells per HPF, 
lymphovascular invasion and a tumor depth exceeding 
7 mm.11-13 Although the gross size of a tumor has no 
significant relationship to prognosis, a tumor depth >7 mm 
predicted both death and lymph node involvement in this 
study. Finally, an infiltrative tumor margin had a dramatic 
influence on local recurrence.2-3 In a great majority of cases, 
a well-handled specimen and an expert pathology and 
oncology department can help the attending surgeon achieve 
a definitive diagnosis.
Cutaneous EP is rarely diagnosed preoperatively; thus, 
surgical management is usually not initially planned. 
Although wide local excision of any cutaneous tumor is 
recommended, the results from historical series suggest that 
EPs with an infiltrative pattern may benefit from further 
surgery if doubts exists regarding the completeness of the 
excision.2-4,8 Because of the high rate of local recurrence, 
a wide excision of the primary tumor, with histologically 
clear margins, is mandatory.7 Proper surgical resection 
leads to curative outcomes in 70% to 80% of cases.3-5,14-15 
However, micrographic surgery has been attempted to 
reduce the morbidity and local recurrence with good initial 
results.14 There are no strong data available favoring adjuvant 
therapy in this setting. Anecdotal reports show some benefits 
when utilizing radiation or chemotherapy.16-17 Barzi et 
al. proposed a new protocol that utilizes isotretinoin and 
interferon alpha to treat metastatic disease, yielding hopeful 
results.12 Nevertheless, there are few studies addressing the 
application of chemotherapy to EP without metastasis.17
EP is still very challenging for surgeons and medical/
radiation oncologists. Because of its rarity, morphologic 
peculiarity and ambiguous similarity to other carcinomas, 
guidelines and strong recommendations are not widely 
available. However, professionals involved in skin cancer 
treatment should be aware of this disease. Because the cases 
are rare and each center has only a few of them, publications 
from cooperative multicentric groups are needed. These 
groups are able to pool several patients getting a larger 
number of cases and increasing the data relevance in order 
to facilitate clinical decisions when dealing with such an 
intriguing neoplasia.
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